Brad Berigan currently serves as the Director of GPO National Accounts for Amgen Oncology US, where he leverages his extensive background in biopharmaceutical account management and sales to drive strategic initiatives that enhance patient access to innovative oncology therapies. With a proven track record of...
Brad Berigan currently serves as the Director of GPO National Accounts for Amgen Oncology US, where he leverages his extensive background in biopharmaceutical account management and sales to drive strategic initiatives that enhance patient access to innovative oncology therapies. With a proven track record of success, Brad has been instrumental in developing and executing comprehensive account strategies that align with Amgen's mission to deliver groundbreaking treatments to patients in need. His leadership was recognized in 2022 when he was honored with the prestigious Chairman’s Circle award and named Coach of the Year, underscoring his commitment to excellence and team development.
In his role, Brad oversees key projects that involve collaboration with national group purchasing organizations (GPOs) to optimize pricing and access strategies for Amgen's oncology portfolio. His expertise in managed care and oncology sales enables him to navigate complex market dynamics, ensuring that healthcare providers have the necessary resources to deliver high-quality care. Brad's authentic and sociable approach fosters strong relationships with stakeholders, while his decisive and competitive nature drives results that contribute to Amgen's growth and leadership in the biopharmaceutical industry.
Brad’s analytical skills and sharp problem-resolution capabilities allow him to dissect intricate market challenges and devise effective solutions that enhance operational efficiency. His comprehensive understanding of pharmaceutical sales, marketing, and training further equips him to lead high-performing teams that are well-prepared to meet the evolving needs of the oncology landscape. As a passionate advocate for patient access, Brad remains committed to advancing Amgen's mission through innovative strategies and collaborative partnerships that ultimately improve patient outcomes.
